Want to see MCK full AI Analyst Report?
Operating Expense Breakdown
Details core costs like R&D, marketing, and admin, offering insight into how efficiently the company runs and where it’s prioritizing investment.SG&A is the dominant, recurring cost and its quarter-to-quarter spikes look more like seasonal, integration, or year‑end adjustments than a structural problem; that makes expense control the key lever for margins. Claims and litigation were a major source of volatility in 2020 but have largely normalized, removing a significant earnings overhang. The stop‑start pattern in restructuring/impairment (including recent reversals) aligns with management’s portfolio reshaping and the planned Medical‑Surgical separation—a financing/transition cost that could cause near‑term earnings noise even as core segments drive higher profitability.
Date | Goodwill Impairment | Selling, Distribution, General, and Administrative | Claims and Litigation | Restructuring, Impairment, and Other |
|---|---|---|---|---|
Jun 30, 2026 | $0.00 | $2.26B | -$34.00M | $136.00M |
Mar 31, 2026 | $0.00 | $1.80B | -$1.00M | $99.00M |
Dec 31, 2025 | $0.00 | $2.03B | $0.00 | $36.00M |
Sep 30, 2025 | $0.00 | $2.07B | -$2.00M | $63.00M |
Jun 30, 2025 | $0.00 | $2.20B | $0.00 | $47.00M |
Mar 31, 2025 | $0.00 | $1.98B | $0.00 | -$73.00M |
Dec 31, 2024 | $0.00 | $2.03B | $0.00 | $32.00M |
Sep 30, 2024 | $0.00 | $2.50B | -$4.00M | $171.00M |
Jun 30, 2024 | $0.00 | $2.00B | $112.00M | $10.00M |
Mar 31, 2024 | $0.00 | $2.19B | $149.00M | $31.00M |